Abstract
Impairment of the complex regulatory network of cell death and survival is frequently the reason for therapy resistance of breast cancer cells and a major cause of tumor progression. We established two independent cell lines from a fast growing mouse breast tumor (WAP-SVT/t transgenic animal). Cells from one line (ME-A cells) are sensitive to apoptotic stimuli such as growth factor depletion or treatment with antitumor agents (e.g. doxorubicin). Cells from the second line (ME-C cells), which carry a missense mutation at the p53 codon 242, are very insensitive to apoptotic stimuli. Co-cultivation experiments revealed that the ME-C cells mediate cell death resistance to the ME-A cells. Microarray and Western blot analysis showed that osteopontin (OPN) is selectively overexpressed by the ME-C cells. This glycoprotein is the most abundant protein secreted by the ME-C cells and we obtained strong indications that OPN is the main antiapoptotic factor. However, the OPN containing ME-C cell medium does not alter the expression level of pro- or antiapoptotic genes or known inhibitors of apoptosis (IAPs). Its signaling involves mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)1/2 as the kinase inhibitor PD98059 restores apoptosis but not the Akt inhibitor. In the ME-A cells, mitochondrial cytochrome c release occurs with and without external apoptotic stimuli. OPN containing ME-C cell medium does not prevent the mitochondrial cytochrome c release and caspase-9 processing. In serum starved ME-A cells, the OPN containing ME-C cell medium prevents caspase-3 activation. However, in doxorubicin-treated cells, although apoptosis is blocked, it does not inhibit caspase-3. This indicates that the ME-A cells distinguish between the initial apoptotic stimuli and that the cells possess a further uncharacterized control element acting downstream from caspase-3.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR . (2003). Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5: 647–654.
Ashkenazi A, Dixit VM . (1998). Death receptors: signaling and modulation. Science 281: 1305–1319.
Beere HM . (2004). The stress of dying: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 117: 2641–2651.
Brown JM, Attardi LD . (2005). The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5: 231–237.
Caudevilla C, Da Silva-Azevedo L, Berg B, Guhl E, Graessmann M, Graessmann A . (2001). Heterologous HIV-nef mRNA trans-splicing: a new principle how mammalian cells generate hybrid mRNA and protein molecules. FEBS Lett 507: 269–279.
Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES . (2005). Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390: 285–292.
Costantini P, Bruey JM, Castedo M, Métivier D, Loeffler M, Susin SA et al. (2002). Pre-processed caspase-9 contained in mitochondria participates in apoptosis. Cell Death Differ 9: 82–88.
Denhardt DT, Guo X . (1993). Osteopontin: a protein with diverse functions. FASEB J 7: 1475–1482.
Erhardt P, Schremser EJ, Cooper GM . (1999). B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19: 5308–5315.
Fujita E, Jinbo A, Matuzaki H, Konishi H, Kikkawa U, Momoi T . (1999). Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9. Biochem Biophys Res Commun 264: 550–555.
Furger KA, Menon RK, Tuck AB, Bramwell VHC, Chambers AF . (2001). The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1: 621–632.
Gardai SJ, Whitlock BB, Qun Xiao Y, Bratton DB, Henson PM . (2004). Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem 279: 44695–44703.
Green DR, Reed JC . (1998). Mitochondria and apoptosis. Science 281: 1309–1312.
Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW . (1995). A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 270: 26232–26238.
Hu P, Han Z, Couvillon AD, Exton JH . (2004). Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J Biol Chem 279: 49420–49429.
Igney FH, Krammer PH . (2002). Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277–288.
Jiang X, Wang X . (2004). Cytochrome c-mediated apoptosis. Annu Rev Biochem 73: 87–106.
Johnson CR, Jarvis WD . (2004). Caspase-9 regulation: an update. Apoptosis 9: 423–427.
Kanda H, Miura M . (2004). Regulatory roles of JNK in programmed cell death. J Biochem 136: 1–6.
Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, SØrensen ES, Denhartd DT . (2002). J. Cell. Biochem. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85: 728–736.
Klein A, Guhl E, Zollinger R, Tzeng YJ, Wessel R, Hummel M et al. (2005). Gene expression profiling: cell cycle deregulation and aneuploidy do not cause breast cancer formation in WAP-SVT/t transgenic animals. J Mol Med 83: 362–376.
Kohlhoff S, Ziechmann C, Gottlob K, Graessmann M . (2000). SV40 T/t-antigens sensitize mammary gland epithelial cells to oxidative stress and apoptosis. Free Radic Biol Med 29: 497–506.
Krause D, Lyons A, Fennelly C, O'Connor R . (2001). Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicoumarol. J Biol Chem 276: 19244–19252.
Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O et al. (2004). NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol 166: 369–380.
LaCasse EC, Baird S, Korneluk RG, MacKenzie AE . (1998). The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247–3259.
Lin YH, Yang-Yen HF . (2001). The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276: 46024–46030.
Mitra SK, Hanson DA, Schlaepfer DD . (2005). Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56–68.
Morimoto I., Sasaki Y, Ishida S, Imai K, Tokino T . (2002). Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes and Cancer 33: 270–278.
Nechushtan A, Smith CL, Lamensdorf I, Yoon S H, Youle RJ . (2001). Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 153: 1265–1276.
Nomura M, Shimizu S, Sugiyama T, Narita M, Ito T, Matsuda H et al. (2003). 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 278: 2058–2065.
Osaki M, Oshimura M, Ito H . (2004). PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667–676.
Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW . (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934–2949.
Reed JC . (2001). Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med 7: 314–319.
Riedl SJ, Shi Y . (2004). Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897–907.
Schimmer AD . (2004). Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64: 7183–7190.
Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB, Mukherjee BB . (1997). Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry 36: 5729–5738.
Shevchenko A, Wilm M, Vorm O, Mann M . (1996). Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850–856.
Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES . (1998). Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1: 949–957.
Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D et al. (1997). Substrate specificities of caspase family proteases. J Biol Chem 272: 9677–9682.
Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. (2000). Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288: 870–874.
Tuck AB, Chambers AF . (2001). The role of osteopontin in breast cancer: clinical and experimental studies. J of Mammary Gland Biology and Neoplasia 6: 419–429.
Tzeng YJ, Guhl E, Graessmann M, Graessmann A . (1993). Breast cancer formation in transgenic animals induced by the whey acidic protein SV40 T antigen (WAP-SV-T) hybrid gene. Oncogene 8: 1965–1971.
Tzeng YJ, Zimmermann C, Guhl E, Berg B, Avantaggiati ML, Graessmann A . (1998). SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors. Oncogene 16: 2103–2114.
Wai PY, Kuo PC . (2004). The role of Osteopontin in tumor metastasis. J Surg Res 121: 228–241.
Weber GF, Ashkar S, Glimcher MJ, Cantor H . (1996). Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271: 509–512.
Wessel R, Foos V, Aspelmeier A, Juergens M, Graessmann A, Klein A . (2006). CorrXpression - identification of significant groups of genes and experiments by means of correspondence analysis and ratio analysis. In Silico Biol 6: 0007.
Acknowledgements
We thank Dr L Da Silva-Azevedo for his help performing the 2D electrophoresis, Dr R Nuck for the chromatography on Superdex G200 and Dr A Corfield for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Graessmann, M., Berg, B., Fuchs, B. et al. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 26, 2840–2850 (2007). https://doi.org/10.1038/sj.onc.1210096
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210096
Keywords
This article is cited by
-
Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression
Oncogene (2021)
-
scMAGeCK links genotypes with multiple phenotypes in single-cell CRISPR screens
Genome Biology (2020)
-
Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment
Clinical Epigenetics (2016)
-
Osteopontin splice variants are differential predictors of breast cancer treatment responses
BMC Cancer (2016)
-
Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells
Tumor Biology (2016)